Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours

Daiichi Sankyo reports positive Phase I trial results for DS-9606, an ADC targeting CLDN6 in advanced solid tumours, showing promising safety, tolerability, and clinical activity.